Safety and Tolerability of Moxonidine in the Treatment of Hypertension
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 19 (3) , 191-203
- https://doi.org/10.2165/00002018-199819030-00003
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The effects of environmental and lifestyle factors on blood pressure and the intermediary role of the sympathetic nervous system1997
- Drug withdrawal and rebound hypertension: Differential action of the central antihypertensive drugs moxonidine and clonidineCardiovascular Drugs and Therapy, 1996
- Future Management of High Blood PressureJournal of Cardiovascular Pharmacology, 1996
- Aspects of Tolerability of Centrally Acting Antihypertensive DrugsJournal of Cardiovascular Pharmacology, 1996
- Epidemiology of hypertensionThe Lancet, 1994
- Moxonidine and Hydrochlorothiazide in Combination: A Synergistic Antihypertensive EffectJournal of Cardiovascular Pharmacology, 1994
- Introduction: Is hypertension a metabolic disease?American Heart Journal, 1993
- Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.The Journal of Pharmacology and Experimental Therapeutics, 1993
- Influence of food on the oral bioavailability of moxonidineEuropean Journal of Drug Metabolism and Pharmacokinetics, 1992
- An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medullaBrain Research, 1988